The Food and Drug Administration (FDA) announced their approval of the first prescription ocular corticosteroid for short-term use in treating dry eye syndrome.
Eysuvis is manufactured by Kala Pharmaceuticals and is a loteprednol etabonate ophthalmic suspension.
Unlike current ophthalmic solutions, Restasis, Allergan, Xiidra and Novartis which can take weeks or months for patients to experience the full benefit, Eysuvis will provide patients immediate relief from the symptoms of dry eye syndrome because of the quick action of corticosteroids against inflammation. Clinical trial participants noted improvement in their symptoms within 1 or 2 days of using the drop.
However, treatment with Eysuvis is approved for a course of up to two weeks. Thus, it is not designed for long-term therapy. The hope is that the drops will take the edge off the inflammation and in turn lessen the need for chronic treatment.
VisiVite offers dry eye support options in the form of supplements.